Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q1 FY22 results · Apr–Jun 2021
Glenmark Pharmaceuticals reported revenue from operations of ₹2,964.89 crore (up 26.4% from Q1 FY21) and net profit of ₹306.53 crore (up 20.7% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,964.89 | 2,344.79 | +26.4% | 2,859.90 | +3.7% |
| Other income | 58.65 | 58.51 | +0.2% | 8.49 | +590.6% |
| Total income | 3,023.54 | 2,403.30 | +25.8% | 2,868.39 | +5.4% |
| Profit before tax | 443.55 | 357.61 | +24.0% | 337.51 | +31.4% |
| Net profit for the period | 306.53 | 254.04 | +20.7% | 233.87 | +31.1% |
| Attributable to shareholders of the company | 399.13 | — | — | — | — |
| EPS, basic (₹) | 10.86 | 9.00 | +20.7% | 8.29 | +31.0% |
| Net margin (%) | 10.3 | 10.8 | 8.2 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,142.12 | 1,682.92 | +27.3% | 1,850.37 | +15.8% |
| Other income | 138.21 | 134.85 | +2.5% | 116.86 | +18.3% |
| Total income | 2,280.32 | 1,817.77 | +25.4% | 1,967.23 | +15.9% |
| Profit before tax | 598.40 | 575.84 | +3.9% | 373.36 | +60.3% |
| Net profit for the period | 489.42 | 462.48 | +5.8% | 341.77 | +43.2% |
| EPS, basic (₹) | 17.34 | 16.39 | +5.8% | 12.11 | +43.2% |
| Net margin (%) | 22.8 | 27.5 | 18.5 |
Consolidated
- Filed with BSE
- 14 Aug 2021, 14:42 IST
- Board meeting
- 13 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Aug 2021, 14:42 IST
- Board meeting
- 13 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE